RE:RE:RE:RE:RE:RE:RE:RE:SEDDS (self emulsifying drug delivery systems)Olaf123, LABS has no cash constraints. CEO statements from last CC puts that to rest and a bonus, a plan to generate more cash in the near term. What Avicanna does is their business but I will admit, being health/medical/pharma focused with a drug in the approval process in Brazil, at least they have the right company profite IF LABS is looking to acquire again but then M&A is a two edged knife, we could be acquired by their global pharma partner.
With the cold war going on globally, the U.S. is also facing a variety of drug shortages, the CDC, NIH, and DEA are facing that problem...like the U.S. is spending 10's of Billions to bring semiconductor manufacturing capacity domestically, I also see new cannabinoid API drugs in the same way, bring production home to North America (Canada and U.S.) with a new class of drugs.
I'm not worried about a thing, LABS is delivering goods new and is the only 1 company in all of North America capable of supplying new API's. We have at least a 2 to 3 year lead on anybody out there.